Overview
Quinidine is a D-isomer of quinine present in the bark of the Cinchona tree and similar plant species. This alkaloid was first described in 1848 and has a long history as an antiarrhythmic medication. Quinidine is considered the first antiarrhythmic drug (class Ia) and is moderately efficacious in the acute conversion of atrial fibrillation to normal sinus rhythm. It prolongs cellular action potential by blocking sodium and potassium currents. A phenomenon known as “quinidine syncope” was first described in the 1950s, characterized by syncopal attacks and ventricular fibrillation in patients treated with this drug. Due to its side effects and increased risk of mortality, the use of quinidine was reduced over the next few decades. However, it continues to be used in the treatment of Brugada syndrome, short QT syndrome and idiopathic ventricular fibrillation.
Indication
Quinidine is indicated for the management and prophylactic therapy of atrial fibrillation/flutter, as well as the suppression of recurrent documented ventricular arrhythmias. It is also used in the treatment of Brugada syndrome, short QT syndrome and idiopathic ventricular fibrillation..
Associated Conditions
- Atrial Fibrillation or Flutter
- Malaria caused by Plasmodium falciparum
- Pseudobulbar Affect (PBA)
- Ventricular Arrhythmia
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/05/19 | Phase 1 | Recruiting | |||
2025/05/16 | Phase 1 | Active, not recruiting | |||
2025/02/26 | Phase 1 | Completed | |||
2024/11/26 | Phase 1 | Completed | |||
2024/07/10 | Phase 1 | Recruiting | |||
2022/10/26 | Phase 1 | Completed | |||
2022/10/25 | Phase 2 | ENROLLING_BY_INVITATION | |||
2022/07/06 | Phase 1 | Completed | |||
2021/03/05 | Phase 1 | Completed | |||
2018/11/28 | Phase 1 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Eon Labs, Inc. | 0185-1047 | ORAL | 300 mg in 1 1 | 9/13/2019 | |
| Sun Pharmaceutical Industries, Inc. | 53489-141 | ORAL | 324 mg in 1 1 | 2/1/2018 | |
| Carilion Materials Management | 68151-2701 | ORAL | 324 mg in 1 1 | 2/13/2015 | |
| Otsuka America Pharmaceutical, Inc | 59148-053 | ORAL | 10 mg in 1 1 | 12/31/2022 | |
| Eon Labs, Inc. | 0185-4346 | ORAL | 200 mg in 1 1 | 9/13/2019 | |
| Eywa Pharma Inc | 71930-016 | ORAL | 324 mg in 1 1 | 12/29/2021 | |
| Carilion Materials Management | 68151-1991 | ORAL | 200 mg in 1 1 | 10/4/2012 | |
| EPIC PHARMA, LLC | 42806-513 | ORAL | 200 mg in 1 1 | 12/15/2021 | |
| Richmond Pharmaceuticals, Inc. | 54738-901 | ORAL | 324 mg in 1 1 | 3/6/2019 | |
| EPIC PHARMA, LLC | 42806-512 | ORAL | 300 mg in 1 1 | 12/15/2021 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Quinidine Sulfate Tablets | 国药准字H11020970 | 化学药品 | 片剂 | 11/27/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.